TOP > 外国特許検索 > PEPTIDE FOR CANCER IMMUNOTHERAPY AND METHOD USING SAME

PEPTIDE FOR CANCER IMMUNOTHERAPY AND METHOD USING SAME UPDATE コモンズ

外国特許コード F130007351
整理番号 2010-024
掲載日 2013年5月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP059878
国際公開番号 WO 2012141201
国際出願日 平成24年4月11日(2012.4.11)
国際公開日 平成24年10月18日(2012.10.18)
優先権データ
  • 特願2011-086962 (2011.4.11) JP
発明の名称 (英語) PEPTIDE FOR CANCER IMMUNOTHERAPY AND METHOD USING SAME UPDATE コモンズ
発明の概要(英語) [Problem] To discover a peptide useful for immunotherapy of liver cancer, and to provide an effective treatment method and early diagnosis method.
[Solution] A peptide comprising an amino acid sequence of any of (1)-(6) below and having immunity-inducing activity. AYPMPFITTI (1) AYCETHYNQL (2) FLVQSSDFKV (3) ILFVQYFHRV (4) KLTLKNKFV (5) ELYHEQCFV (6)
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer, and elucidation of the pathogenesis, diagnosis, therapy is being advanced, many advanced cancer is currently impossible to treat. In order to improve this, the development of therapeutic effective early diagnosis method is demanded. Is renal cancer, a tumor marker specific since they are not, early diagnosis is difficult.
A method of treating cancer is one of the immunotherapy. Conventional immunotherapy done around the non-specific immunotherapy have been, in recent years, in vivo tumor rejection T cells play an important role was revealed, cytotoxic T cells capable of inducing T (CTL: Cytotoxic T Lymphocyte) cell recognition of the tumor antigen MHC class I restricted epitopes isolation and specific is demanded. However, many tumor antigen isolated cytotoxic T cells were used as cDNA expression cloning method has been performed, cytotoxic T cell lines and tumor cells are necessary for the establishment of, a tumor antigen from carcinomas other than melanoma has been difficult to isolate.
Peptide vaccine immunotherapy using, for lung cancer SART, adjunct MAGE peptide vaccine, peptide vaccine therapy for cancer and spleen HLA-A24SART, hematologic malignancies, gastrointestinal, breast, urinary, reproductive organs such as the WT1 peptide vaccine therapy for cancer such as most of the solid, and many reports, are those associated with renal cancer (non-patent document 1-6). Non-patent document 1-3 is, disclosed CA9 peptide vaccine therapy. However, by vaccination can induce specific cytotoxic T cells but, and very limited clinical effect, cancer patients of the 23 partial reduction was seen at only 2 name. CA9 Kidney cancer (pale clear cell) expression of approximately 100% but, at present the utility as a vaccine is not high. Non-patent document 4 is, mutant VHL peptide vaccine therapy, non-patent document 5 is, disclosed WT1 peptide vaccine therapy. However, only a small clinical study, the clinical effect that is very limited. Non-patent document 6 is, the induction of cytotoxic T cells by the peptide HIFPH 3 - diones. However, it was demonstrated that specific cytotoxic T cell derived although, in the clinical study from now on.
In this way the reason for the limited clinical efficacy, immunity to the cancer antigen, actually does not function well from a living body is considered. Of the expression amount of cancerous tissue in a screened as high as the antigen, target actually immunotherapy is not always good.
Associated with the prior art, also Patent Document 1-6. Patent Document 1 is, mainly relates to esophageal cancer, esophageal cancer using microarrays cDNA found antigen, antigen from an amino acid sequence with the peptide of the disclosed vaccine therapy. Also Patent Document 2-6, in kidney cancer or vaccine. However, in the prior art, is a peptide useful in the immunotherapy of kidney cancer is found without the, diagnostic methods for early stage or vaccine has not yet been obtained.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA CITY UNIVERSITY
  • 発明者(英語)
  • KAWASHIMA Hidenori
  • OBAYASHI Aiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close